One of the major challenges of pancreatic cancer that contributes to its poor survival rates is its resistance to many treatments such as chemotherapy. Heterogeneity of the tumor, the dense fibroblastic stroma, and the aggressive biology of the tumor all contribute to it being a difficult to treat tumor. Furthermore, as the aggressive tumor grows into adjacent tissues, it can invade into the liver or the stomach, and more often invades into critical blood vessels, rendering the tumor inoperable. As surgical resection is currently the only chance for cure, a locally advanced tumor that is inoperable leaves patients in a state where only palliative care may be offered. ACT is developing a technology that will convert patients with locally advanced inoperable disease into candidates for surgical resection, by shrinking the tumor away from these vital structures, improving quality of life and extending survival.